-
Deltamethrin-Induced Ferroptosis Impairs Offspring Memory vi
2026-05-25
This study elucidates how maternal exposure to deltamethrin (DM) during gestation and lactation impairs hippocampal-dependent learning and memory in male offspring by activating p53-mediated ferroptosis. The research provides mechanistic insights relevant for neurotoxicity modeling and offers actionable protocols for exploring p53 inhibition as a neuroprotective strategy.
-
Calpain Inhibitor I, ALLN: Technical Application Guide
2026-05-25
Calpain Inhibitor I, ALLN is designed for precise inhibition of calpain and cathepsin proteases, supporting workflows in apoptosis assays, ischemia-reperfusion injury models, and inflammation research. Researchers should use this compound where selective control of proteolytic activity is essential, and avoid applications requiring water solubility or diagnostic use.
-
IWP-L6: Unraveling Wnt Metabolic Integration via Porcupine I
2026-05-24
Explore how IWP-L6, a potent Porcupine inhibitor, enables researchers to dissect the metabolic and post-translational dimensions of Wnt signaling. This article uniquely bridges recent O-GlcNAcylation findings to practical assay design and advanced morphogenesis applications.
-
VX-745: Precision p38α MAPK Inhibitor for Inflammation Model
2026-05-23
VX-745 stands out as a highly selective p38α MAPK inhibitor, enabling reproducible suppression of inflammatory cytokines and robust modeling of disease pathways. This guide unpacks applied workflows, troubleshooting strategies, and innovative assay design based on the latest mechanistic insights.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–Receptor Bindi
2026-05-22
This study reveals that naturally occurring angiotensin peptides, including short C- and N-terminal fragments, significantly enhance binding between the SARS-CoV-2 spike protein and its cellular receptors, particularly AXL. These findings deepen our understanding of the interplay between the renin-angiotensin system and viral pathogenesis, suggesting new directions for research on COVID-19 mechanisms and therapeutic targets.
-
NFIA Orchestrates Bone Cell Fate: Mechanisms in Bone Homeost
2026-05-22
The reference study identifies nuclear factor I/A (NFIA) as a critical, previously underappreciated regulator of bone homeostasis by coordinating osteoclast and osteoblast differentiation in mesenchymal stem/progenitor cells. These findings offer new mechanistic insight into bone mass regulation and osteoporosis, with implications for both basic research and translational bone biology workflows.
-
UGDH Phosphorylation Drives Prostate Cancer Growth and Resis
2026-05-21
This study uncovers phosphorylation of UDP-glucose dehydrogenase (UGDH) at serine 316 as a key regulator of glycosaminoglycan biosynthesis, cell motility, spheroid growth, and therapeutic resistance in prostate cancer. The findings highlight UGDH phosphorylation as a potential control point for modulating tumor phenotype and resistance to androgen receptor inhibition.
-
Translational Immunometabolism: CAY10499 as a Precision Lipa
2026-05-21
Explore how CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, empowers translational researchers to dissect and modulate lipid-driven immune mechanisms. This article bridges mechanistic insight with actionable strategy, contextualizing CAY10499’s unique role in immunometabolic studies and offering protocol guidance for advanced lipid signaling and macrophage research.
-
Abiraterone Acetate in Precision Prostate Cancer Models
2026-05-20
Explore Abiraterone acetate's role as a CYP17 inhibitor in advanced prostate cancer research. This article provides a unique, practical analysis of its use in patient-derived 3D spheroid models, revealing new assay insights for translational workflows.
-
Peptidisc-Assisted Clustering Enables Multimeric Nanobody En
2026-05-20
Chen and Duong van Hoa introduce a peptidisc-based strategy to induce hydrophobic clustering, enabling the generation of multimeric and multispecific nanobody assemblies termed 'polybodies.' This method enhances affinity and versatility in protein engineering, expanding the toolkit for constructing complex, functional protein architectures.
-
Fulvestrant (ICI 182,780): Advanced Mechanistic Insights for
2026-05-19
Explore Fulvestrant (ICI 182,780) with a deep dive into its mechanism, unique post-translational effects, and research applications in endocrine therapy resistance. This article provides new perspectives for scientists pursuing advanced breast cancer investigations.
-
Protoporphyrin IX: Translating Mechanistic Insight to Oncolo
2026-05-19
This thought-leadership article explores Protoporphyrin IX’s pivotal role in heme biosynthesis, ferroptosis resistance, and photodynamic cancer strategies. Bridging foundational biochemistry with translational research, it provides actionable guidance for experimentalists, highlighting APExBIO’s high-purity offering and emerging research on the METTL16-SENP3-LTF axis in hepatocellular carcinoma. The piece differentiates itself by integrating recent mechanistic insights, competitive context, and workflow-specific protocol parameters.
-
Everolimus (RAD001): Strategic mTOR Inhibition for Translati
2026-05-18
This thought-leadership article unites mechanistic insight with strategic guidance for translational researchers leveraging Everolimus (RAD001) in cancer research. Integrating key findings from Schwartz’s dissertation on in vitro drug response evaluation, it delivers actionable recommendations for experimental design, competitive benchmarking, and translational impact. The discussion distinguishes itself by bridging nuanced in vitro metrics with translational workflow strategy, and by contextualizing APExBIO’s Everolimus offering within a broader research and clinical landscape.
-
Necrostatin-1: Precision RIP1 Kinase Inhibitor for Necroptos
2026-05-18
Necrostatin-1 sets the benchmark as a selective, potent RIP1 kinase inhibitor for dissecting necroptosis and inflammatory cell death signaling in both in vitro and in vivo models. Its reproducibility and broad applicability empower researchers to unravel disease mechanisms and optimize workflows in acute kidney injury and liver necroptosis investigations.
-
RG7388 MDM2 Antagonist: Precision p53 Pathway Activation in
2026-05-17
RG7388 stands out as a next-generation, selective MDM2 antagonist, enabling robust p53 pathway activation and apoptosis in wild-type p53 cancer cells. Its superior potency and synergy in combination therapies make it a pivotal tool for translational oncology research, with optimized protocols and troubleshooting strategies enhancing experimental reliability.